Danish pharmaceutical giant Novo Nordisk is partnering with OpenAI to integrate artificial intelligence across its operations. The move aims to accelerate drug discovery, optimize manufacturing and supply chains, and improve commercial efficiency.
This collaboration will leverage OpenAI's technology to analyze complex datasets and identify promising drug candidates. Drugmakers are increasingly turning to AI to streamline development processes, from clinical trials to regulatory filings.
Novo Nordisk, facing intense competition in the lucrative weight-loss drug market, seeks to regain ground. Analysts project annual revenues from obesity drugs to surpass $100 billion within the next decade.
The partnership will roll out pilot programs in research, development, manufacturing, and commercial sectors, with full integration anticipated by the end of 2026. OpenAI will also assist in training Novo Nordisk's global workforce to enhance AI literacy and boost overall productivity.
Novo Nordisk CEO Mike Doustdar emphasized that the goal is to "supercharge" scientists, not replace them, aiming to increase productivity and manage future hiring needs more effectively. OpenAI CEO Sam Altman stated the collaboration will "accelerate scientific discovery, run smarter global operations, and redefine the future of patient care."
The agreement includes robust data protection, governance, and human oversight, building upon Novo Nordisk's existing AI initiatives.